BR112022025306A2 - Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina - Google Patents

Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina

Info

Publication number
BR112022025306A2
BR112022025306A2 BR112022025306A BR112022025306A BR112022025306A2 BR 112022025306 A2 BR112022025306 A2 BR 112022025306A2 BR 112022025306 A BR112022025306 A BR 112022025306A BR 112022025306 A BR112022025306 A BR 112022025306A BR 112022025306 A2 BR112022025306 A2 BR 112022025306A2
Authority
BR
Brazil
Prior art keywords
composition
dimethyltriptamine
methoxin
benzoate salt
benzoate
Prior art date
Application number
BR112022025306A
Other languages
English (en)
Inventor
Feilding-Mellen Cosmo
Mason Timothy
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008961.1A external-priority patent/GB202008961D0/en
Priority claimed from GBGB2008968.6A external-priority patent/GB202008968D0/en
Priority claimed from GBGB2008964.5A external-priority patent/GB202008964D0/en
Priority claimed from GBGB2101634.0A external-priority patent/GB202101634D0/en
Priority claimed from GBGB2101640.7A external-priority patent/GB202101640D0/en
Priority claimed from GBGB2102100.1A external-priority patent/GB202102100D0/en
Priority claimed from GBGB2102095.3A external-priority patent/GB202102095D0/en
Priority claimed from GBGB2105047.1A external-priority patent/GB202105047D0/en
Priority claimed from GBGB2105049.7A external-priority patent/GB202105049D0/en
Priority claimed from GBGB2105462.2A external-priority patent/GB202105462D0/en
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of BR112022025306A2 publication Critical patent/BR112022025306A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO COMPREENDENDO UM SAL BENZOATO DE 5-METÓXIN,N-DIMETILTRIPTAMINA. Uma composição compreendendo uma quantidade farmaceuticamente eficaz de um sal benzoato farmaceuticamente aceitável de 5-metóxi-N,N-dimetiltriptamina (5MeODMT).
BR112022025306A 2020-06-12 2021-06-14 Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina BR112022025306A2 (pt)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB2008961.1A GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GBGB2008968.6A GB202008968D0 (en) 2020-06-12 2020-06-12 Phamaceutical composition
GBGB2008964.5A GB202008964D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2019241.5A GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
GBGB2101634.0A GB202101634D0 (en) 2021-02-05 2021-02-05 Pharmaceutical composition
GBGB2101640.7A GB202101640D0 (en) 2021-02-05 2021-02-05 Pharmaceutical composition
GBGB2102100.1A GB202102100D0 (en) 2021-02-15 2021-02-15 Pharmaceutical composition
GBGB2102095.3A GB202102095D0 (en) 2021-02-15 2021-02-15 Pharmaceutical composition
GBGB2105047.1A GB202105047D0 (en) 2021-04-08 2021-04-08 Pharmaceutical composition
GBGB2105049.7A GB202105049D0 (en) 2021-04-08 2021-04-08 Pharmaceutical composition
GBGB2105462.2A GB202105462D0 (en) 2021-04-16 2021-04-16 Pharmaceutical composition
PCT/GB2021/051475 WO2021250434A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Publications (1)

Publication Number Publication Date
BR112022025306A2 true BR112022025306A2 (pt) 2023-02-28

Family

ID=76641719

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025306A BR112022025306A2 (pt) 2020-06-12 2021-06-14 Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina

Country Status (10)

Country Link
US (6) US11518742B2 (pt)
EP (3) EP3941904A1 (pt)
JP (1) JP2023530292A (pt)
KR (1) KR20230024378A (pt)
CN (1) CN116056762A (pt)
AU (1) AU2021289147A1 (pt)
BR (1) BR112022025306A2 (pt)
CA (1) CA3187020A1 (pt)
IL (1) IL298871A (pt)
WO (2) WO2021250435A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220092509A (ko) 2019-10-01 2022-07-01 엠피리언 뉴로사이언스, 인크. 트립타민 발현을 조절하는 균류의 유전자 공학
JP2023530292A (ja) 2020-06-12 2023-07-14 ベックリー・サイテック・リミテッド ５－メトキシ－ｎ，ｎ－ジメチルトリプタミンの安息香酸塩を含む組成物
CA3220214A1 (en) * 2021-05-26 2022-12-01 Abdelmalik Slassi Hallucinogen-fatty acid combination
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4159192A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
WO2023111544A2 (en) * 2021-12-13 2023-06-22 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
AU2022425541A1 (en) 2021-12-30 2024-06-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023137094A1 (en) * 2022-01-12 2023-07-20 Eleusis Therapeutics Us, Inc. Psilocin benzoate formulation for intravenous infusion
WO2023186806A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder
FI4313945T3 (fi) 2022-03-27 2024-05-23 Gh Res Ireland Limited 5-meo-dmt:n kiteinen hydrobromidisuola
WO2023186827A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US20240101514A1 (en) * 2022-08-19 2024-03-28 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024105379A1 (en) * 2022-11-14 2024-05-23 Beckley Psytech Limited Formulations of 5-meo-dmt

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2774763A (en) 1956-12-18 Preparation of amides of lysergic age
US2997470A (en) 1956-03-05 1961-08-22 Lilly Co Eli Lysergic acid amides
US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles
GB981192A (en) 1960-03-30 1965-01-20 Westminster Bank Ltd Improvements in or relating to 4 hydroxytryptamine esters
US3224945A (en) 1963-05-06 1965-12-21 College Of Pharmacy Process for the production of ergot alkaloids
BE792515A (fr) 1971-12-10 1973-06-08 Sandoz Sa Nouveaux derives de l'acide lysergique, leur preparation et leur application comme medicaments
CH578565A5 (en) 1972-12-07 1976-08-13 Sandoz Ag N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity
HU172649B (hu) 1975-04-24 1978-11-28 Gyogyszerkutato Intezet Sposob poluchenija novykh biologicheski aktivnykh lizergamidov
GB1584464A (en) 1977-04-19 1981-02-11 Farmaceutici Italia Ergot alkaloids
EP0026899A1 (de) 1979-10-09 1981-04-15 Sandoz Ag Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung
WO2001015677A2 (en) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
AU2002230423A1 (en) 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
KR100523257B1 (ko) * 2000-12-29 2005-10-24 삼성전자주식회사 포지티브형 감광성 폴리이미드 전구체 및 이를 포함하는조성물
NZ537770A (en) 2002-06-21 2007-03-30 Suven Life Sciences Ltd Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
ES2571730T3 (es) 2006-06-28 2016-05-26 Lundbeck Na Ltd Composiciones farmacéuticas que comprenden droxidopa
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010054202A2 (en) 2008-11-06 2010-05-14 Leon Rosenberg Package of pills useful for titration and method of titrating a patient
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
US20130281401A1 (en) * 2010-10-07 2013-10-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN103816150A (zh) 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
WO2018195455A1 (en) 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3713568A1 (en) 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
BR112020018306A2 (pt) 2018-03-08 2020-12-22 New Atlas Biotechnologies Llc. Processos para a produção de triptaminas
US10813116B2 (en) 2018-05-11 2020-10-20 Apple Inc. Support of advanced user equipment (UE) minimum processing times in new radio (NR) systems
US20210267966A1 (en) 2018-06-21 2021-09-02 Robert Joseph Petcavich Method of Inducing Dendritic and Synaptic Genesis in Neurodegenerative Chronic Diseases
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
AU2019396627A1 (en) 2018-12-14 2021-07-15 Harvest Bio Llc A digital therapeutic component to optimize induction of buprenorphine-containing products
KR20210154966A (ko) * 2019-02-22 2021-12-21 지에이치 리서치 아일랜드 리미티드 우울증을 치료하기 위한 5-메톡시-n,n-디메틸트립타민 (5-meo-dmt)
CR20210436A (es) 2019-02-22 2021-11-02 Gh Res Ireland Limited Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
AU2020231231A1 (en) 2019-03-07 2021-10-07 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US20230000883A1 (en) 2019-04-17 2023-01-05 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
GB201911024D0 (en) * 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
CA3149602A1 (en) 2019-08-25 2021-03-04 Andrew R. Chadeayne Alkyl quarternary ammonium tryptamines and their therapeutic uses
PT3844147T (pt) 2019-11-07 2022-07-04 Small Pharma Ltd Compostos
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
CN115916215A (zh) 2020-04-16 2023-04-04 长矛治疗股份有限公司 迷幻剂衍生物的经皮微剂量递送
US20210322743A1 (en) 2020-04-20 2021-10-21 Indian Institute Of Technology Bombay Microneedle array patch for drug delivery and production method thereof
WO2021222885A1 (en) 2020-05-01 2021-11-04 Zosano Pharma Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
JP2023524764A (ja) 2020-05-05 2023-06-13 ユニヴェルシテートスピタル バーゼル Ｌｓｄ、シロシビン、又は他のサイケデリック薬の急性の情動効果プロフィールを向上させるためのｍｄｍａ治療
JP2023530292A (ja) 2020-06-12 2023-07-14 ベックリー・サイテック・リミテッド ５－メトキシ－ｎ，ｎ－ジメチルトリプタミンの安息香酸塩を含む組成物
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CN113288883A (zh) 2021-05-24 2021-08-24 河南科技大学 一种长效缓解抑郁微针贴片及其制备方法

Also Published As

Publication number Publication date
US20230382858A1 (en) 2023-11-30
US20220267267A1 (en) 2022-08-25
CA3187020A1 (en) 2021-12-16
US20220259147A1 (en) 2022-08-18
US20230348381A1 (en) 2023-11-02
WO2021250435A1 (en) 2021-12-16
WO2021250434A1 (en) 2021-12-16
EP3941583A1 (en) 2022-01-26
IL298871A (en) 2023-02-01
US11603353B2 (en) 2023-03-14
US20230031944A1 (en) 2023-02-02
CN116056762A (zh) 2023-05-02
US11518742B2 (en) 2022-12-06
AU2021289147A1 (en) 2023-02-02
US20220396552A1 (en) 2022-12-15
EP3941583B1 (en) 2023-02-22
EP3941904A1 (en) 2022-01-26
US11518743B2 (en) 2022-12-06
JP2023530292A (ja) 2023-07-14
US11680044B2 (en) 2023-06-20
EP4279070A3 (en) 2023-12-20
EP4279070A2 (en) 2023-11-22
KR20230024378A (ko) 2023-02-20
EP3941583B9 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
BR112022025306A2 (pt) Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
IL288617A (en) Medical preparations containing partially or fully deuterated n,n-dimethyltryptamine compounds
MX2022015207A (es) Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
GB2596884B8 (en) A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
CO2020014586A2 (es) Compuestos
CR20120414A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
CO6390117A2 (es) Regimen de dosificación para un agonista de los receptores de s1p
CY1114983T1 (el) Συνθεση για τη θεραπεια της κυστικης ινωσης
PH12018500047A1 (en) Notch pathway signaling inhibitor compounds
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EA201070483A1 (ru) Новые офтальмологические композиции
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EA202092383A1 (ru) Ингибиторы комплемента на основе замещенного бензофурана, бензопиррола, бензотиофена и их структурных производных
CL2021000196A1 (es) Método de tratamiento de la epilepsia
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?
CL2021001675A1 (es) Una composición para el cuidado bucal.
AR110770A1 (es) Moduladores del canal de potasio
PH12020551117A1 (en) Compositions for preventing or treating uveitis
BR112022004677A2 (pt) Composição oftálmica para o tratamento de uveíte
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование